Literature DB >> 23221034

Routine screening for Cushing's syndrome is not required in patients presenting with hirsutism.

Z Karaca1, B Acmaz, G Acmaz, F Tanriverdi, K Unluhizarci, S Aribas, Y Sahin, F Kelestimur.   

Abstract

CONTEXT: Prevalence of Cushing's syndrome (CS) in patients presenting with hirsutism is not well known.
OBJECTIVE: Screening of CS in patients with hirsutism.
SETTING: Referral hospital. PATIENTS AND OTHER PARTICIPANTS: This study was carried out on 105 patients who were admitted to the Endocrinology Department with the complaint of hirsutism. INTERVENTION: All the patients were evaluated with low-dose dexamethasone suppression test (LDDST) for CS. MAIN OUTCOME MEASURE: Response to LDDST in patients presenting with hirsutism.
RESULTS: All the patients had suppressed cortisol levels following low-dose dexamethasone administration excluding CS. The etiology of hirsutism was polycystic ovary syndrome in 79%, idiopathic hirsutism in 13%, idiopathic hyperandrogenemia in 6%, and nonclassical congenital hyperplasia in 2% of the patients.
CONCLUSION: Routine screening for CS in patients with a referral diagnosis of hirsutism is not required. For the time being, diagnostic tests for CS in hirsute patients should be limited to patients who have accompanying clinical stigmata of hypercortisolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23221034     DOI: 10.1530/EJE-12-0938

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  2 in total

1.  Molecular skin changes in Cushing syndrome and the effects of treatment.

Authors:  Z Karaca; S Taheri; S T Firat; M Borlu; G Zararsiz; E Mehmetbeyoglu; A Sezgin Caglar; A Hacioglu; F Tanriverdi; K Unluhizarci; F Kelestimur
Journal:  J Endocrinol Invest       Date:  2020-05-14       Impact factor: 4.256

2.  Symptomatic Cushing syndrome and hyperandrogenemia revealing steroid cell ovarian neoplasm with late intra-abdominal metastasis.

Authors:  Menghua Yuan; Mingcai Qiu; Mei Zhu
Journal:  BMC Endocr Disord       Date:  2014-02-08       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.